Molecular architecture of the ErbB2 extracellular domain homodimer

Oncotarget

Volumn 6, Issue 3, 2015, Pages 1695-1706

  Hu, Shi ^a,b,c,d   Sun, Yuna ^b,c   Meng, Yanchun ^e,f,g   Wang, Xiaoze ^e   Yang, Weili ^d,e   Fu, Wenyan ^d   Guo, Huaizu ^a,f   Qian, Weizhu ^a,f   Hou, Sheng ^a,d,f,g   Li, Bohua ^a,d   Rao, Zihe ^b,c   Lou, Zhiyong ^c   Guo, Yajun ^a,d,e,f,g  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b INSTITUTE OF BIOPHYSICS   (China)

^c Tsinghua University   (China)

^d CHINESE PLA GENERAL HOSPITAL   (China)

^e NANKAI UNIVERSITY   (China)

^f Municipal Water Resource Development and Utilization (South)   (China)

^g LIAOCHENG UNIVERSITY   (China)

Author keywords

Crystal structure; Dimerization; ErbB2; Oncogene; Signal transduction

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; HOMODIMER; PERTUZUMAB; TRASTUZUMAB; ERBB2 PROTEIN, HUMAN;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DIMERIZATION; DRUG TARGETING; EXTRACELLULAR DOMAIN; HUMAN; HUMAN CELL; MUTAGENESIS; NONHUMAN; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; SIGNAL TRANSDUCTION; AMINO ACID SEQUENCE; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; CHLOROCEBUS AETHIOPS; COS 1 CELL LINE; FEMALE; GENETICS; MOLECULAR GENETICS; ONCOGENE; PROTEIN CONFORMATION; PROTEIN MULTIMERIZATION; PROTEIN TERTIARY STRUCTURE; SITE DIRECTED MUTAGENESIS; TUMOR CELL LINE;

AMINO ACID SEQUENCE; ANIMALS; CELL LINE, TUMOR; CERCOPITHECUS AETHIOPS; COS CELLS; FEMALE; HUMANS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; ONCOGENES; PROTEIN CONFORMATION; PROTEIN MULTIMERIZATION; PROTEIN STRUCTURE, TERTIARY; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION;

EID: 84922719872     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2713     Document Type: Article

References (30)

1. Alroy I, Yarden Y. The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions. FEBS Lett. 1997; 410:83-86.
2. Citri A, Yarden Y. EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol. 2006; 7:505-516.
3. Burgess AW, Cho HS, Eigenbrot C, Ferguson KM, Garrett TP, Leahy DJ, Lemmon MA, Sliwkowski MX, Ward CW, Yokoyama S. An open-and-shut case?. Recent insights into the activation of EGF/ErbB receptors. Mol Cell. 2003; 12:541-552.
4. Tao R-H, Maruyama IN. All EGF (ErbB) receptors have preformed homo-and heterodimeric structures in living cells. Journal of cell science. 2008; 121:3207-3217.
5. Klapper LN, Glathe S, Vaisman N, Hynes NE, Andrews GC, Sela M, Yarden Y. The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. Proceedings of the National Academy of Sciences. 1999; 96:4995-5000.
6. Cho HS, Mason K, Ramyar KX, Stanley AM, Gabelli SB, Denney DW, Jr., Leahy DJ. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature. 2003; 421:756-760.
7. Beerli RR, Graus-Porta D, Woods-Cook K, Chen X, Yarden Y, Hynes NE. Neu differentiation factor activation of ErbB-3 and ErbB-4 is cell specific and displays a differential requirement for ErbB-2. Molecular and cellular biology. 1995; 15:6496-6505.
8. Graus-Porta D, Beerli RR, Hynes NE. Single-chain antibody-mediated intracellular retention of ErbB-2 impairs Neu differentiation factor and epidermal growth factor signaling. Mol Cell Biol. 1995; 15:1182-1191.
9. Karunagaran D, Tzahar E, Beerli RR, Chen X, Graus-Porta D, Ratzkin B, Seger R, Hynes NE, Yarden Y. ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. The EMBO journal. 1996; 15:254.
10. Berger MB, Mendrola JM, Lemmon MA. ErbB3/HER3 does not homodimerize upon neuregulin binding at the cell surface. FEBS letters. 2004; 569:332-336.
11. Franklin MC, Carey KD, Vajdos FF, Leahy DJ, de Vos AM, Sliwkowski MX. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell. 2004; 5:317-328.
12. Ogiso H, Ishitani R, Nureki O, Fukai S, Yamanaka M, Kim JH, Saito K, Sakamoto A, Inoue M, Shirouzu M, Yokoyama S. Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell. 2002; 110:775-787.
13. Fu W, Wang Y, Zhang Y, Xiong L, Takeda H, Ding L, Xu Q, He L, Tan W, Bethune AN, Zhou L. Insights into HER2 signaling from step-by-step optimization of anti-HER2 antibodies, mAbs. 2014; 6:978-990.
14. Penuel E, Akita RW, Sliwkowski MX. Identification of a region within the ErbB2/HER2 intracellular domain that is necessary for ligand-independent association. J Biol Chem. 2002; 277:28468-28473.
15. Shi Y, Huang W, Tan Y, Jin X, Dua R, Penuel E, Mukherjee A, Sperinde J, Pannu H, Chenna A, DeFazio-Eli L, Pidaparthi S, Badal Y, Wallweber G, Chen L, Williams S, et al. A novel proximity assay for the detection of proteins and protein complexes: quantitation of HER1 and HER2 total protein expression and homodimerization in formalin-fixed, paraffin-embedded cell lines and breast cancer tissue. Diagn Mol Pathol. 2009; 18:11-21.
16. Agus DB, Akita RW, Fox WD, Lewis GD, Higgins B, Pisacane PI, Lofgren JA, Tindell C, Evans DP, Maiese K, Scher HI, Sliwkowski MX. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell. 2002; 2:127-137.
17. Muthuswamy SK, Gilman M, Brugge JS. Controlled dimerization of ErbB receptors provides evidence for differential signaling by homo-and heterodimers. Mol Cell Biol. 1999; 19:6845-6857.
18. Alvarado D, Klein DE, Lemmon MA. ErbB2 resembles an autoinhibited invertebrate epidermal growth factor receptor. Nature. 2009; 461:287-291.
19. Schlessinger J. Ligand-induced, receptor-mediated dimerization and activation of EGF receptor. Cell. 2002; 110:669-672.
20. Bublil EM, Yarden Y. The EGF receptor family: spearheading a merger of signaling and therapeutics. Curr Opin Cell Biol. 2007; 19:124-134.
21. Jorissen RN, Walker F, Pouliot N, Garrett TP, Ward CW, Burgess AW. Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res. 2003; 284:31-53.
22. Pawson T. Specificity in signal transduction: from phosphotyrosine-SH2 domain interactions to complex cellular systems. Cell. 2004; 116:191-203.
23. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. 2000; 103:211-225.
24. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001; 2:127-137.
25. Garrett TP, McKern NM, Lou M, Elleman TC, Adams TE, Lovrecz GO, Zhu HJ, Walker F, Frenkel MJ, Hoyne PA, Jorissen RN, Nice EC, Burgess AW, Ward CW. Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha. Cell. 2002; 110:763-773.
26. Brennan PJ, Kumagai T, Berezov A, Murali R, Greene MI. HER2/Neu: mechanisms of dimerization/oligomerization. Oncogene. 2002; 21:328.
27. Chantry A. The kinase domain and membrane localization determine intracellular interactions between epidermal growth factor receptors. Journal of Biological Chemistry. 1995; 270:3068-3073.
28. Garrett TP, McKern NM, Lou M, Elleman TC, Adams TE, Lovrecz GO, Kofler M, Jorissen RN, Nice EC, Burgess AW, Ward CW. The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors. Mol Cell. 2003; 11:495-505.
29. Alvarado D, Klein DE, Lemmon MA. Structural basis for negative cooperativity in growth factor binding to an EGF receptor. Cell. 2010; 142:568-579.
30. Diermeier-Daucher S, Hasmann M, Brockhoff G. Flow cytometric FRET analysis of erbB receptor interaction on a cell-by-cell basis. Ann N Y Acad Sci. 2008; 1130:280-286.